FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000744663> ?p ?o ?g. }

• W2000744663 endingPage "1181" @default.
• W2000744663 startingPage "1181" @default.
• W2000744663 abstract "The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (Jan 22, p 253)1Heart Outcomes Prevention Evaluation (HOPE) Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.Lancet. 2000; 355: 253-259Summary Full Text Full Text PDF PubMed Scopus (3298) Google Scholar report that ramipril given to people with diabetes mellitus lowered the risk of major cardiovascular outcomes by 25–30%. They claim that the effect was apparent irrespective of whether participants had a history of cardiovascular events, hypertension, or microalbuminuria, were taking insulin or oral hypoglycaemic agents, or had type-1 or type-2 diabetes mellitus. The investigators also state that ramipril lowered the risk of overt nephropathy, renal failure, or laser therapy, and that it had no long-term effect on glycaemic control. Although these results are interesting, several critical points can be raised, and it can also be argued that the new information given in the paper is limited. Figure 2 shows that the relative risk reduction in subgroups without microalbuminuria, with no cardiovascular disease and with type-1 diabetes do not reach significance despite high numbers of patients: without microalbuminuria (n=2437) and with no cardiovascular disease (n=1119). Since more than 98% of the patients had type-2 diabetes mellitus it is obvious that no conclusions of the effect of ramipril in type-1 diabetes mellitus can be drawn from the study. Thus, only in patients with diabetes with microalbuminuria or cardiovascular disease, or both, at high risk of having cardiovascular events, is the relative risk reduction significant. No data on metabolic control and blood pressure as absolute figures are given in the paper. We are only told that blood pressure and glycated haemoglobin (HbA1c) are significantly lower in the ramipril group, but for HbA1c the difference is not shown. Thus, it can be argued that the findings in this study only confirm what has been shown in the UK Prospective Diabetes Study.2UK Prospective Diabetes Study (UKPDS) GroupEfficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.BMJ. 1998; 317: 713-720Crossref PubMed Google Scholar In the conclusion the investigators claim that ramipril lowered the risk of nephropathy, renal failure, or laser therapy. Ramipril does indeed reduce the risk of developing nephropathy in patients with microalbuminuria, as previous studies have shown.3Ravid M Lang R Rachmani R Lishner M Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7 year follow-up study.Arch Intern Med. 1996; 156: 286-289Crossref PubMed Scopus (0) Google Scholar However, table 3 shows that there was no effect on laser therapy (p=0·70) nor dialysis (p=0·70) in the ramipril group. The results of the HOPE study in patients with diabetes mellitus are important but mostly because they confirm previous studies. The study underlines the importance of strict metabolic control and aggressive antihypertensive treatment in high-risk patients with type-2 diabetes who have cardiovascular disease or microalbuminuria. However, it is not shown that patients with uncomplicated type-2 diabetes, with only one additional risk factor, will benefit from angiotensin-convertingenzyme (ACE) inhibitor treatment. Nor is it shown that there are new effects of ACE-inhibitors on end-stage manifestations of diabetic nephropathy or proliferative retinopathy. The HOPE study and diabetesAuthors' reply Full-Text PDF" @default.
• W2000744663 created "2016-06-24" @default.
• W2000744663 creator A5074997674 @default.
• W2000744663 date "2000-04-01" @default.
• W2000744663 modified "2023-09-26" @default.
• W2000744663 title "The HOPE study and diabetes" @default.
• W2000744663 cites W1604542334 @default.
• W2000744663 cites W4242344507 @default.
• W2000744663 cites W4294140790 @default.
• W2000744663 doi "https://doi.org/10.1016/s0140-6736(00)02076-6" @default.
• W2000744663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10791397" @default.
• W2000744663 hasPublicationYear "2000" @default.
• W2000744663 type Work @default.
• W2000744663 sameAs 2000744663 @default.
• W2000744663 citedByCount "5" @default.
• W2000744663 crossrefType "journal-article" @default.
• W2000744663 hasAuthorship W2000744663A5074997674 @default.
• W2000744663 hasBestOaLocation W20007446631 @default.
• W2000744663 hasConcept C126322002 @default.
• W2000744663 hasConcept C134018914 @default.
• W2000744663 hasConcept C2776174234 @default.
• W2000744663 hasConcept C2777180221 @default.
• W2000744663 hasConcept C2779134260 @default.
• W2000744663 hasConcept C2779888176 @default.
• W2000744663 hasConcept C2781184683 @default.
• W2000744663 hasConcept C2781203188 @default.
• W2000744663 hasConcept C2910068830 @default.
• W2000744663 hasConcept C555293320 @default.
• W2000744663 hasConcept C71924100 @default.
• W2000744663 hasConcept C84393581 @default.
• W2000744663 hasConceptScore W2000744663C126322002 @default.
• W2000744663 hasConceptScore W2000744663C134018914 @default.
• W2000744663 hasConceptScore W2000744663C2776174234 @default.
• W2000744663 hasConceptScore W2000744663C2777180221 @default.
• W2000744663 hasConceptScore W2000744663C2779134260 @default.
• W2000744663 hasConceptScore W2000744663C2779888176 @default.
• W2000744663 hasConceptScore W2000744663C2781184683 @default.
• W2000744663 hasConceptScore W2000744663C2781203188 @default.
• W2000744663 hasConceptScore W2000744663C2910068830 @default.
• W2000744663 hasConceptScore W2000744663C555293320 @default.
• W2000744663 hasConceptScore W2000744663C71924100 @default.
• W2000744663 hasConceptScore W2000744663C84393581 @default.
• W2000744663 hasIssue "9210" @default.
• W2000744663 hasLocation W20007446631 @default.
• W2000744663 hasLocation W20007446632 @default.
• W2000744663 hasOpenAccess W2000744663 @default.
• W2000744663 hasPrimaryLocation W20007446631 @default.
• W2000744663 hasRelatedWork W1967067560 @default.
• W2000744663 hasRelatedWork W1985804667 @default.
• W2000744663 hasRelatedWork W2022968272 @default.
• W2000744663 hasRelatedWork W2071715316 @default.
• W2000744663 hasRelatedWork W2392809328 @default.
• W2000744663 hasRelatedWork W2416284561 @default.
• W2000744663 hasRelatedWork W2434391732 @default.
• W2000744663 hasRelatedWork W3005682875 @default.
• W2000744663 hasRelatedWork W4297830739 @default.
• W2000744663 hasRelatedWork W4380836650 @default.
• W2000744663 hasVolume "355" @default.
• W2000744663 isParatext "false" @default.
• W2000744663 isRetracted "false" @default.
• W2000744663 magId "2000744663" @default.
• W2000744663 workType "article" @default.